Nelson Dusetti
May 15, 2025, 09:14
Nelson Dusetti: SCHEMA-PDAC was selected for funding by the ARC French Foundation for Cancer Research
Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn:
“We are honored to announce that our project SCHEMA-PDAC (Single-cell and ChEmotherapy resistance Mapping in PDAC) has been selected for funding by the ARC French foundation for Cancer Research (ARC-France)!
This 3-year translational research program conducted at The Cancer Research Centre of Marseille and Marseille Cancer Center aims to decipher how pancreatic tumors evolve under chemotherapy pressure, combining spatial and single-cell transcriptomics with clonal tracking and functional validation to uncover resistant cell populations and design personalized therapeutic strategies.
A key feature of this project is the development and clinical application of PANCProfiler, a deconvolution-based tool that leverages next-generation transcriptomic signatures to quantify distinct tumor cell subpopulations and predict treatment response. This innovation bridges preclinical models and patient care, paving the way for more precise and adaptive therapeutic approaches.
A huge thanks to the ARC Foundation, whose unwavering support for innovative cancer research is helping drive meaningful advances in the fight against cancer.”
More posts featuring Nelson Dusetti on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 15, 2025, 09:08
May 15, 2025, 08:58
May 15, 2025, 08:46
May 15, 2025, 07:00
May 15, 2025, 06:40
May 15, 2025, 06:21